Guides · PeptideU · 8 min read

Survodutide Results Timeline: What Studies Measured, and When

The short answer

Published survodutide research did not report week-by-week changes. Instead, trials fixed a small number of assessment points: a dose-escalation phase followed by a week-46 endpoint in a phase 2 obesity trial, and a week-48 liver biopsy endpoint in a phase 2 MASH trial. Later reports extended the horizon into phase 3 and an event-driven cardiovascular outcomes trial. This page describes those measurement timepoints and what researchers reported at each, without implying what any individual would experience.

Survodutide is an investigational once-weekly glucagon receptor and GLP-1 receptor dual agonist that has been evaluated in randomised phase 2 trials in obesity and in metabolic dysfunction-associated steatohepatitis (MASH) (Lancet Diabetes Endocrinol, 2024) (NEJM, 2024). A review of incretin-based and dual or triple agonist pharmacology described the rationale for combining glucagon receptor activity with GLP-1 receptor activity in metabolic liver disease (Aliment Pharmacol Ther, 2025). This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical decision.

Why "timeline" means something different in trials

A common assumption is that a drug has a weekly progression that can be charted. Published clinical research does not work that way. Trials pre-specify a limited number of assessment points — often an escalation period, a maintenance period and one primary endpoint visit — and the peer-reviewed abstracts report what was measured at those points. For survodutide, the published record centres on two phase 2 readouts, at week 46 in obesity (Lancet Diabetes Endocrinol, 2024) and at week 48 in MASH with fibrosis (NEJM, 2024), plus a later report of once-weekly survodutide in adults with obesity (NEJM, 2026).

There is no published week-by-week survodutide dataset. Granular early timepoints such as week 4, week 8 or week 12 were not the reported endpoints in these trials, so any "week 4 versus week 12" framing would not reflect what researchers actually published.

Timepoints that appear in the published record

Timepoint	What the trial structure or report covered
Weeks 0–20 (obesity phase 2)	A dose-escalation period preceded maintenance dosing in the dose-finding trial that tested survodutide 0.6, 2.4, 3.6 and 4.8 mg once weekly against placebo (Lancet Diabetes Endocrinol, 2024).
Week 46 (obesity phase 2)	The primary endpoint visit at which percentage change in body weight from baseline was assessed (Lancet Diabetes Endocrinol, 2024).
Weeks 0–24 (MASH phase 2)	A rapid dose-escalation period preceded maintenance dosing at 2.4, 4.8 or 6.0 mg once weekly (NEJM, 2024).
Week 48 (MASH phase 2)	The end-of-treatment biopsy endpoint, scoring histologic improvement in MASH without worsening of fibrosis (NEJM, 2024).
Phase 3 obesity reporting	A trial of once-weekly survodutide in adults with obesity was reported in the New England Journal of Medicine (NEJM, 2026).
Multi-year, event-driven	The rationale and design of the SYNCHRONIZE cardiovascular outcomes trial of survodutide in obesity were published separately (JACC Heart Fail, 2024).

Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.

Try it free

The obesity phase 2 trial: escalation, then a week-46 endpoint

The dose-finding phase 2 trial was described as a randomised, double-blind, placebo-controlled study of survodutide in adults with obesity, with doses of 0.6, 2.4, 3.6 and 4.8 mg once weekly reached through a 20-week dose-escalation period before a maintenance period (Lancet Diabetes Endocrinol, 2024). The design detail matters for anyone reading a timeline: for roughly the first third of the study, participants were not yet at their assigned maintenance dose, so the dose in the body during early weeks differed from the dose named in the trial arms (Lancet Diabetes Endocrinol, 2024).

At the week-46 endpoint, researchers reported mean percentage reductions in body weight of approximately 6.2% with 0.6 mg, 12.5% with 2.4 mg, 13.2% with 3.6 mg and 14.9% with 4.8 mg, compared with approximately 2.8% with placebo (Lancet Diabetes Endocrinol, 2024). Those figures describe group averages in a trial population under study conditions; they are not a schedule and not an individual forecast.

Systematic reviews of emerging obesity pharmacotherapy placed survodutide among glucagon/GLP-1 dual agonists in development alongside other incretin-based agents and summarised their phase 2 weight outcomes (Pharmacol Rev, 2025), and a clinical overview of weight management in obesity similarly grouped dual receptor agonists among investigational options (Med Clin, 2025).

What the abstracts did not break down

Mean weight change specifically at week 4, 8 or 12 was not the reported endpoint in the dose-finding trial (Lancet Diabetes Endocrinol, 2024).
Time-to-first-change or "onset" metrics were not framed as endpoints in the published phase 2 obesity report (Lancet Diabetes Endocrinol, 2024).
Post-treatment follow-up trajectories were not the focus of the week-46 primary analysis (Lancet Diabetes Endocrinol, 2024).

The MASH phase 2 trial: a 48-week histology clock

In MASH, the measurement horizon was set by liver biopsy rather than by scales or scans. The phase 2 randomised trial assigned adults with biopsy-confirmed MASH and fibrosis to survodutide 2.4, 4.8 or 6.0 mg once weekly or placebo, with a 24-week rapid dose-escalation period followed by treatment through week 48 (NEJM, 2024).

At week 48, the study reported histologic improvement in MASH with no worsening of fibrosis in roughly 47%, 62% and 43% of participants in the 2.4 mg, 4.8 mg and 6.0 mg groups, versus about 14% with placebo (NEJM, 2024). Researchers also reported that larger proportions of survodutide-treated participants than placebo participants met secondary endpoints for reduction in liver fat content and for improvement in fibrosis without worsening of MASH at that same visit (NEJM, 2024).

The important timeline lesson is that histologic endpoints are slow by design. A narrative review of incretin and dual agonist therapy in metabolic liver disease described glucagon receptor engagement as a mechanism of interest for hepatic fat handling in MASH programmes (World J Gastroenterol, 2024), and a review of therapeutic horizons in MASH set survodutide within a pipeline where biopsy-based endpoints typically require many months of treatment (J Clin Invest, 2025). A systematic review and network meta-analysis compared pharmacological therapies in MASH for fibrosis regression and MASH resolution across trials (Hepatology, 2025).

Tracking research? Log entries with dates, lots and notes — records, never plans.

Get the app

Longer horizons: phase 3 and outcome trials

Beyond the phase 2 readouts, once-weekly survodutide in adults with obesity was reported in a later New England Journal of Medicine paper (NEJM, 2026). Separately, investigators published the rationale and design of the SYNCHRONIZE cardiovascular outcomes trial of survodutide for the treatment of obesity (JACC Heart Fail, 2024). Cardiovascular outcomes programmes of that type are structured around accrued events rather than a fixed short endpoint, which places their reporting horizon years rather than weeks after randomisation (JACC Heart Fail, 2024).

A broader review of obesity medications discussed outcomes beyond weight itself across multiple organ systems, a category of endpoint that generally requires extended follow-up to assess (Lancet Diabetes Endocrinol, 2026). A review of GLP-1 medicines in type 2 diabetes and obesity likewise summarised efficacy and safety across the incretin class in which survodutide's dual-agonist approach sits (Diabetes Care, 2024).

How to read a survodutide "timeline" honestly

Match the number to its visit. The 14.9% mean weight reduction figure belongs specifically to the 4.8 mg arm at week 46 in the dose-finding trial (Lancet Diabetes Endocrinol, 2024), not to an earlier or later moment.
Account for escalation. Both phase 2 trials built in escalation periods of 20 weeks in obesity (Lancet Diabetes Endocrinol, 2024) and 24 weeks in MASH (NEJM, 2024), so early-phase exposure differed from maintenance exposure.
Distinguish endpoint type. A body-weight endpoint at week 46 (Lancet Diabetes Endocrinol, 2024) and a biopsy endpoint at week 48 (NEJM, 2024) are not interchangeable measures of the same thing.
Treat group means as group means. Reviews summarising emerging obesity pharmacotherapy reported averages across randomised populations, not individual trajectories (Pharmacol Rev, 2025).

Want the full course? Every compound, evidence-graded and cited, inside PeptideU.

Start learning free

Tolerability Over Time: What Studies Report

Adverse-event reporting in these trials was aggregated across the treatment period rather than resolved week by week. In the phase 2 obesity dose-finding trial, researchers reported that gastrointestinal adverse events — including nausea, vomiting and diarrhoea — were more frequent with survodutide than with placebo (Lancet Diabetes Endocrinol, 2024). In the phase 2 MASH trial, the study likewise reported that adverse events including nausea, diarrhoea and vomiting occurred more often among participants assigned to survodutide than among those assigned to placebo (NEJM, 2024).

Class-level reviews of GLP-1-based medicines described gastrointestinal effects as the most common tolerability issue across incretin therapies in type 2 diabetes and obesity (Diabetes Care, 2024), and a systematic review of emerging obesity pharmacotherapies discussed safety and tolerability alongside efficacy for agents in development, survodutide among them (Pharmacol Rev, 2025). Because the published abstracts did not break tolerability data into discrete week-4 or week-12 windows, statements about when adverse events "peak" or "fade" cannot be drawn from these sources (Lancet Diabetes Endocrinol, 2024).

Where the evidence is thin

Survodutide remains investigational, and the peer-reviewed timeline record is concentrated in two phase 2 trials plus later obesity and outcomes-trial reporting (Lancet Diabetes Endocrinol, 2024) (NEJM, 2024) (NEJM, 2026). Comparative positioning against other agents in MASH has been examined through indirect methods rather than head-to-head trials in a network meta-analysis of fibrosis regression and MASH resolution (Hepatology, 2025), and reviews of the MASLD and MASH pipeline noted that dual and triple agonist programmes were still maturing (Aliment Pharmacol Ther, 2025) (J Clin Invest, 2025). Readers encountering confident week-by-week claims should check whether the underlying paper reported that timepoint at all.

Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.

Try it free

References

Frequently asked questions

Did any survodutide trial report results at week 4, 8 or 12?▾

Not as published endpoints. The phase 2 obesity dose-finding trial reported body-weight change at week 46 after a 20-week escalation period (PMID 38330987), and the phase 2 MASH trial reported histology at week 48 after a 24-week escalation period (PMID 38847460). Early-week breakdowns were not the reported outcomes in those abstracts.

What did researchers report at week 46 in the obesity trial?▾

The study reported mean body-weight reductions of roughly 6.2%, 12.5%, 13.2% and 14.9% for survodutide 0.6, 2.4, 3.6 and 4.8 mg once weekly, versus about 2.8% with placebo, at week 46 (PMID 38330987). Those are group averages in a randomised trial population, not predictions for any individual person.

Why do the MASH trial timelines run to 48 weeks?▾

Histologic endpoints require extended treatment. The phase 2 MASH trial assessed improvement in MASH without worsening of fibrosis at week 48 (PMID 38847460), and reviews of the MASH pipeline described biopsy-based endpoints as a slow, months-long measurement framework across investigational agents (PMID 40590228).

Is there longer-term survodutide data?▾

Once-weekly survodutide in adults with obesity was reported in a later New England Journal of Medicine paper (PMID 42253238), and the rationale and design of the SYNCHRONIZE cardiovascular outcomes trial were published separately (PMID 39453356). Event-driven outcomes trials of that kind report over years rather than weeks.

When did adverse events occur in these trials?▾

Published abstracts aggregated safety across the whole treatment period rather than by week. Researchers reported that gastrointestinal events such as nausea, vomiting and diarrhoea were more common with survodutide than placebo in the obesity dose-finding trial (PMID 38330987) and in the MASH trial (PMID 38847460).

How does survodutide's timeline compare with other agents?▾

Direct head-to-head timing comparisons were not available. A systematic review and network meta-analysis compared pharmacological therapies in MASH for fibrosis regression and MASH resolution using indirect methods (PMID 39903735), and a systematic review of emerging obesity pharmacotherapies summarised agents in development including dual agonists (PMID 39952695).

Does escalation affect how a timeline should be read?▾

Yes. In the obesity trial, assigned maintenance doses were reached through a 20-week escalation period before the week-46 endpoint (PMID 38330987), and the MASH trial used a 24-week rapid escalation before week 48 (PMID 38847460). Exposure during early weeks therefore differed from the dose named in each trial arm.

The PeptideU app

Track it. Calculate it. Actually understand it.

Research trackerLog every entry with dates, lots and notes — records, never plans.

CalculatorsReconstitution, units and dilution maths without the guesswork.

The UniversityEvery compound explained, evidence-graded, cited to the literature.

Get started freePeptideU Premium — $9.99/mo for the full curriculum, advanced tracking & giveaways

Download on theApp Store — Free Get it onGoogle Play

References

18+ · Educational purposes only
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.